ESR1 and breast cancer: We have recently studied, using immunohistochemistry, the expression of GRPR ina large series of primary breast cancers and found that GRPR was overexpressed in 83.2% of ER-positive tumors but only in 12% of ER-negative tumors (p < 0.00001) [2].